Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
作者： Matteo S Carlino , Georgina V Long , Richard F Kefford , Helen Rizos , None
DOI: 10.1016/J.CRITREVONC.2015.08.021
关键词:
摘要: BRAF and MEK inhibitors, alone or in combination, are highly active the 40% of patients with mutant metastatic melanoma. Despite this activity resistance often develops treated these agents. This review summarises biology mitogen activated protein kinase (MAPK) pathway, particular reference to effects inhibitors The clinical molecular predictors response mechanisms discussed detail along biological rationale evidence for future treatment strategies both MAPK inhibitor naive resistant
core.ac.uk
elsevier.com
sci-hub.se 参考文章(178)
Letizia Porcelli, Gabriella Guida, Stefania Tommasi, Michele Guida, Amalia Azzariti, Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib? Cancer Chemotherapy and Pharmacology. ,vol. 76, pp. 433- 438 ,(2015) , 10.1007/S00280-015-2796-6
Mauricio Burotto, Victoria L. Chiou, Jung-Min Lee, Elise C. Kohn, The MAPK pathway across different malignancies: a new perspective. Cancer. ,vol. 120, pp. 3446- 3456 ,(2014) , 10.1002/CNCR.28864
Bianca Devitt, Wendy Liu, Renato Salemi, Rory Wolfe, John Kelly, Chin-Yuan Tzen, Alexander Dobrovic, Grant McArthur, Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma Pigment Cell & Melanoma Research. ,vol. 24, pp. 666- 672 ,(2011) , 10.1111/J.1755-148X.2011.00873.X
Peter Schraml, Holger Moch, Michael J. Mihatsch, Manuel Anabitarte, Daniel Ackermann, James Bruderer, André Fijan, Ronald Simon, Marcus Rist, Kim Wilber, Hartmut Knönagel, Ulrico Schmid, Göran Alund, Jan Richter, Robert Maurer, Guido Sauter, Jean Luc Fehr, Renata Flury, Urs Wagner, Andreas Schönenberger, Franz Hering, Peter Jäger, Thomas Hardmeier, Thomas Gasser, High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Research. ,vol. 61, pp. 4514- 4519 ,(2001)
Alexander M. Menzies, Iwei Yeh, Thomas Botton, Boris C. Bastian, Richard A. Scolyer, Georgina V. Long, Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion Pigment Cell & Melanoma Research. ,vol. 28, pp. 607- 610 ,(2015) , 10.1111/PCMR.12388
Allison Ackerman, Oliver Klein, David F. McDermott, Wei Wang, Nageatte Ibrahim, Donald P. Lawrence, Anasuya Gunturi, Keith T. Flaherty, F. Stephen Hodi, Richard Kefford, Alexander M. Menzies, Michael B. Atkins, Georgina V. Long, Ryan J. Sullivan, Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. ,vol. 120, pp. 1695- 1701 ,(2014) , 10.1002/CNCR.28620
Ruth Halaban, Wengeng Zhang, Antonella Bacchiocchi, Elaine Cheng, Fabio Parisi, Stephan Ariyan, Michael Krauthammer, James P McCusker, Yuval Kluger, Mario Sznol, None, PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells Pigment Cell & Melanoma Research. ,vol. 23, pp. 190- 200 ,(2010) , 10.1111/J.1755-148X.2010.00685.X
Matthew M. K. Chan, Lauren E. Haydu, Alexander M. Menzies, Mary W. F. Azer, Oliver Klein, Megan Lyle, Arthur Clements, Alexander Guminski, Richard F. Kefford, Georgina V. Long, The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition Cancer. ,vol. 120, pp. 3142- 3153 ,(2014) , 10.1002/CNCR.28851
Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F Stephen Hodi, Jacob Schachter, Anna C Pavlick, Karl D Lewis, Lee D Cranmer, Christian U Blank, Steven J O'Day, Paolo A Ascierto, April K S Salama, Kim A Margolin, Carmen Loquai, Thomas K Eigentler, Tara C Gangadhar, Matteo S Carlino, Sanjiv S Agarwala, Stergios J Moschos, Jeffrey A Sosman, Simone M Goldinger, Ronnie Shapira-Frommer, Rene Gonzalez, John M Kirkwood, Jedd D Wolchok, Alexander Eggermont, Xiaoyun Nicole Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, S Peter Kang, Adil Daud, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial The Lancet Oncology. ,vol. 16, pp. 908- 918 ,(2015) , 10.1016/S1470-2045(15)00083-2
Rehan Akbani, KadiráC Akdemir, B áArman Aksoy, Monique Albert, Adrian Ally, SamirkumaráB Amin, Harindra Arachchi, Arshi Arora, J áTodd Auman, Brenda Ayala, Julien Baboud, Miruna Balasundaram, Saianand Balu, Nandita Barnabas, John Bartlett, Pam Bartlett, BorisáC Bastian, StephenáB Baylin, Madhusmita Behera, Dmitry Belyaev, Christopher Benz, Brady Bernard, Rameen Beroukhim, Natalie Bir, AaronáD Black, Tom Bodenheimer, Lori Boice, GenevieveáM Boland, Riccardo Bono, MoizáS Bootwalla, Marcus Bosenberg, Jay Bowen, Reanne Bowlby, ChristopheráA Bristow, Laura Brockway-Lunardi, Denise Brooks, Jakub Brzezinski, Wiam Bshara, Elizabeth Buda, WilliamáR Burns, YaronáS N Butterfield, Michael Button, Tiffany Calderone, GiancarloáAntonini Cappellini, Candace Carter, ScottáL Carter, Lynn Cherney, AndrewáD Cherniack, Aaron Chevalier, Lynda Chin, Juok Cho, RaymondáJ Cho, Yoon-La Choi, Andy Chu, Sudha Chudamani, Kristian Cibulskis, Giovanni Ciriello, Amanda Clarke, Stephen Coons, Leslie Cope, Daniel Crain, Erin Curley, Ludmila Danilova, Stefania D’Atri, Tanja Davidsen, MichaeláA Davies, KeitháA Delman, JohnáA Demchok, QixiaáA Deng, YonathanáLissanu Deribe, Noreen Dhalla, Rajiv Dhir, Daniel DiCara, Michael Dinikin, Michael Dubina, J áStephen Ebrom, Sophie Egea, Greg Eley, Jay Engel, JenniferáM Eschbacher, KonstantináV Fedosenko, Ina Felau, Timothy Fennell, MartináL Ferguson, Sheila Fisher, KeitháT Flaherty, Scott Frazer, Jessica Frick, Victoria Fulidou, StaceyáB Gabriel, Jianjiong Gao, Johanna Gardner, LeviáA Garraway, JulieáM Gastier-Foster, Carmelo Gaudioso, Nils Gehlenborg, Giannicola Genovese, Mark Gerken, JeffreyáE Gershenwald, Gad Getz, Carmen Gomez-Fernandez, Thomas Gribbin, Jonna Grimsby, Benjamin Gross, Ranabir Guin, Tony Gutschner, Angela Hadjipanayis, Ruth Halaban, Benjamin Hanf, David Haussler, LaurenáE Haydu, D áNeil Hayes, NicholasáK Hayward, DavidáI Heiman, Lynn Herbert, JamesáG Herman, Peter Hersey, KatherineáA Hoadley, Eran Hodis, RobertáA Holt, DaveáSB Hoon, Susan Hoppough, AlanáP Hoyle, FranklináW Huang, Mei Huang, Sharon Huang, CarolynáM Hutter, Matthew Ibbs, Lisa Iype, Anders Jacobsen, Valerie Jakrot, Alyssa Janning, WilliamáR Jeck, StuartáR Jefferys, MarkáA Jensen, CorbináD Jones, StevenáJ M Jones, Zhenlin Ju, Hojabr Kakavand, Hyojin Kang, RichardáF Kefford, FadloáR Khuri, Jaegil Kim, JohnáM Kirkwood, Joachim Klode, Anil Korkut, Konstanty Korski, Michael Krauthammer, Raju Kucherlapati, LawrenceáN Kwong, None, Genomic Classification of Cutaneous Melanoma Cell. ,vol. 161, pp. 1681- 1696 ,(2015) , 10.1016/J.CELL.2015.05.044